OAM
REGN icon

Ostrum Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Ostrum Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$574K Sell
920
-145
-14% -$98.7K 0.03% 304
2026
Q1 		$823K Sell
1,065
-3,221
-75% -$2.47M 0.05% 244
2025
Q4 		$3.31M Sell
4,286
-2,145
-33% -$1.46M 0.16% 97
2025
Q3 		$3.62M Buy
6,431
+753
+13% +$426K 0.16% 112
2025
Q2 		$2.98M Buy
5,678
+586
+12% +$327K 0.14% 134
2025
Q1 		$3.23M Buy
5,092
+1,579
+45% +$1.09M 0.17% 111
2024
Q4 		$2.5M Sell
3,513
-584
-14% -$490K 0.22% 145
2024
Q3 		$4.31M Sell
4,097
-925
-18% -$1.03M 0.36% 57
2024
Q2 		$5.28M Buy
5,022
+1,563
+45% +$1.52M 0.46% 37
2024
Q1 		$3.33M Sell
3,459
-143
-4% -$136K 0.26% 108
2023
Q4 		$3.16M Buy
3,602
+842
+31% +$693K 0.28% 110
2023
Q3 		$2.27M Sell
2,760
-2,453
-47% -$1.93M 0.21% 154
2023
Q2 		$3.75M Sell
5,213
-72
-1% -$55.5K 0.31% 87
2023
Q1 		$4.34M Buy
+5,285
New +$3.99M 0.38% 65

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Ostrum Asset Management's REGN Position: Q2 2026 in Review

Ostrum Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, selling an estimated $98.7K and leaving 920 shares worth $574K. The position accounts for 0.03% of the portfolio, ranked #304.

Ostrum Asset Management first reported a position in REGN in Q1 2023 and has held it in 14 quarters since. The position peaked at $5.28M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Ostrum Asset Management held 920 shares of Regeneron Pharmaceuticals worth $574K as of Q2 2026.
  • Ostrum Asset Management sold 145 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $98.7K.
  • Regeneron Pharmaceuticals made up 0.03% of Ostrum Asset Management's portfolio in Q2 2026, its #304 holding.
  • Ostrum Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Ostrum Asset Management's Regeneron Pharmaceuticals position peaked at $5.28M in Q2 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Ostrum Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.